Synonyms: Example 1 [US20090137530] | MT-1303 | MT1303
Compound class:
Synthetic organic
Comment: Amiselimod (MT-1303) is claimed in patent US20090137530 (Compound 1-3 is the hydrochloride used experimentally) as a potential immunomodulatory agent [1]. It is a sphingosine-1-phosphate (SIP) receptor prodrug agonist, similar in action to the approved MS drug fingolimod, but with improved receptor subtype selectivity [3].
Selective SIP1 receptor agonists are being investigated for immunomodulatory/immunosuppresant action in MS and other autoimmune conditions [2]. |
|
Immunopharmacology Disease | |||
Disease | X-Refs | Comment | References |
Relapsing-remitting multiple sclerosis |
Disease Ontology:
DOID:2378 |
Phase 2 clinical candidate for RRMS. | |
Psoriasis |
Disease Ontology:
DOID:8893 |
Phase 2 clinical candidate for plaque psoriasis. | |
Crohn's disease |
Disease Ontology:
DOID:8778 OMIM: 266600 Orphanet: ORPHA206 |
Phase 2 clinical candidate for CD. |